Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO.

Founded in July 2017, Passage Bio Inc. is building a pipeline of programs via a research collaboration with the University of Pennsylvania’s Gene Therapy Program, led by the start-up’s co-founder and Chief Scientific Adviser James Wilson. It has identified three clinical candidates, all of which are due to enter the clinic by 1H21, as well as three other pipeline programs in discovery or at the candidate selection stage...